Medifast, Inc. MED is entering a decisive phase of its turnaround as the Trilivy metabolic-health platform rolls out alongside another round of cost reductions. Management expects progress toward profitability to begin in the fourth quarter of 2026.
The near-term setup remains demanding. Revenues are still well below year-ago levels and the active coach base continues to shrink, leaving the Q4 target dependent on cost execution, steadier sales and better productivity.
MED's Q2 Beat Offers an Early Turnaround Signal
Second-quarter 2026 revenues fell 27.6% year over year to $76.4 million but edged above the Zacks Consensus Estimate of $76 million. The company posted a loss of 28 cents per share, narrower than the consensus loss of 67 cents.
Operating indicators offered some encouragement. Revenue per active earning coach rose 41% year over year to $6,529 and improved for a third consecutive quarter. Management views higher coach productivity as an early indicator because it has historically preceded client acquisition, coach growth and revenue expansion.
Medifast Is Repositioning Around Trilivy
Trilivy succeeds OPTAVIA as Medifast's primary consumer brand and expands the company's focus from traditional weight loss to broader metabolic health. The system is organized around Reset, Refine and Renew phases and is designed to support clients using GLP-1 medications, transitioning off them or pursuing non-medication approaches.
For peer context, investors evaluating Medifast can also look at Mama's Creations, Inc. MAMA and US Foods Holding Corp. USFD. MED's investment case, however, remains centered on whether Trilivy, improving coach productivity and Catalyst-led savings can stabilize revenues and restore profitability.
MED's Catalyst Program Targets More Cost Savings
The Catalyst program is designed to generate millions of dollars in additional savings through facility rationalization, artificial-intelligence-related efficiencies and broader business simplification. These initiatives build on more than $30 million of previously identified cost savings.
Management has not yet quantified the new savings target, but expects to provide more detail with third-quarter results. The objective is to remove costs without impairing revenue growth, making Catalyst an important part of the company's effort to improve profitability while continuing to invest in Trilivy.
Medifast Still Expects Losses Before Q4
Medifast expects third-quarter revenues of $60 million to $80 million and a loss of 15 cents to 65 cents per share, excluding one-time Catalyst-related costs. The company also expects the active earning coach count to keep declining in the near term even as productivity improves.
For 2026, management projects revenues of $270 million to $300 million and a loss of 25 cents to $1.75 per share. The Q4 profitability goal therefore rests on sustained revenue stability, successful commercialization of Trilivy and enough cost savings to offset continued fixed-cost pressure.
MED's Ratings Frame a High-Risk Recovery Story
The turnaround has identifiable catalysts, but valuation adds another consideration. MED trades at 0.5X forward 12-month sales, below the food-miscellaneous sub-industry multiple of 0.81X but above its one-year median of 0.40X. The relative discount may look attractive, though the premium to Medifast's own historical median and the company's shrinking coach network and ongoing losses keep execution risk elevated.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). MED also has a Momentum Score of A, but a Value Score of D, Growth Score of F and VGM Score of D. Since the Style Scores are designed to complement the Zacks Rank, the mix points to favorable momentum characteristics but a less convincing broader profile, supporting a measured view until the recovery becomes more established. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MEDIFAST INC (MED): Free Stock Analysis Report
US Foods Holding Corp. (USFD): Free Stock Analysis Report
Mama's Creations, Inc. (MAMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
